Fig. 1

Effect of rFLT-3 L treatment on leukocytes in blood and tissue compartments of HIS mice. HIS mice were generated by engraftment of cord blood-derived stem cells into NSG mice at 3–4 weeks of age following conditioning irradiation of (125 cGy). Following reconstitution of human leukocyte populations, animals were distributed into groups (untreated n = 4, rFLT-3 L n = 8) and (A) rFLT-3 L was administered via subcutaneous injection (50ug in 250ul PBS, 0.2 mg/mL) once per day on days 0, 4 and 8. LN and spleen were harvested on day 14 for analysis via flow cytometry. Shown are (B) the gating strategy used to select human CD45⁺ leukocytes and further assess distribution of CD3⁺ T, CD14⁺ myeloid, and CD19⁺ B cell populations. (C) Summarized data (mean ± SEM) of the total percentages of human CD45⁺ cells within the leukocyte gate and the CD3⁺, CD14⁺ and CD19⁺ cells as a % of the human CD45⁺ population from the blood, spleen or axillary LN as observed at day 14 resulting from no treatment or administration of rFLT-3 L. Statistical comparisons were made using an unpaired two tailed Student’s T-test with Welch’s correction to determine significance of differences (*p < 0.05, **p < 0.01) due to treatment